Evidence map›Paper›PMID 30268122›Full record

ArticleCardiovascular diabetology2018

Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting.

Silvia Lee, Cihan Ay, Christoph W Kopp, Simon Panzer, Thomas Gremmel

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2YDiabetic medicine : a journal of the British Diabetic Association · 2022
    Article
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Silvia LeeDepartment of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Cihan AyDepartment of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Christoph W KoppDepartment of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Simon PanzerDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
Thomas GremmelDepartment of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.gremmel@meduniwien.ac.at.ORCID 0000-0001-9554-7292
Medical University of Vienna · ATFachhochschule Wiener Neustadt · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs a strong platelet agonist on the one hand and key molecule in plasmatic coagulation on the other hand, thrombin connects primary and secondary hemostasis. Thrombin generation potential reflects the individual capacity to generate thrombin, and has been associated with the occurrence of thromboembolic events. In the current study, we sought to identify predictors of thrombin generation potential in patients undergoing angioplasty and stenting for atherosclerotic cardiovascular disease.

methodsPeak thrombin generation potential and area under the curve (AUC) of thrombin generation potential were determined with a commercially available assay in 315 patients on dual antiplatelet therapy 1 day after percutaneous intervention, and in 100 healthy individuals without cardiovascular disease.

resultsMedian (interquartile range) peak thrombin generation potential and AUC of thrombin generation potential in the study cohort (n = 315) were significantly higher than in healthy individuals (n = 100) without cardiovascular disease (peak thrombin generation potential: 445.4 nM [354.5-551.8 nM] vs. 174.5 nM [141.2-261.2 nM]; AUC of thrombin generation potential: 5262.7 nM thrombin [4806.6-5756.9 nM thrombin] vs. 3405.2 nM thrombin [3043.6-3747.3 nM thrombin]; both p < 0.001). In patients undergoing angioplasty and stenting, hemoglobin A1c (HbA1c) was the only variable that was independently associated with both, peak thrombin generation potential and AUC of thrombin generation potential (both p ≤ 0.007). In contrast, platelet count and high-sensitivity C-reactive protein were only associated with peak thrombin generation potential, and body mass index and serum creatinine were only associated with AUC of thrombin generation potential after adjustment for covariates by multivariate linear regression analyses (all p < 0.05). Patients with HbA1c ≥ 6% had significantly higher peak thrombin generation potential and AUC of thrombin generation potential than patients with HbA1c < 6% (peak thrombin generation potential: 476.9 nM [385.8-577.9 nM] vs. 423.9 nM [335.8-529.5 nM], p = 0.002; AUC of thrombin generation potential: 5371.8 nM thrombin [4903 - 5899 nM thrombin] vs. 5172.5 nM thrombin [4731.8-5664.7 nM thrombin], p = 0.01). HbA1c ≥ 6% remained independently associated with both parameters of thrombin generation potential after multivariate linear regression analyses (both p ≤ 0.02).

conclusionsImpaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting for cardiovascular disease.

Indexed as

StentsAgedAngioplastyAtherosclerosisBiomarkersBlood GlucoseCase-Control StudiesDrug Therapy, CombinationFemaleGlucose IntoleranceGlycated HemoglobinHumansMaleMiddle AgedPlatelet Aggregation InhibitorsThrombinBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanPlatelet Aggregation InhibitorsThrombinAngioplastyDiabetesHbA1cStentingThrombinThrombin generation potential

Identifiers

PMID30268122
PMCPMC6162876
OpenAlexW2893564416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.